Test

Abstract

Background: So far, an ideal vaccine for anthrax has not been approved. PA63 antigen has antigenic properties and they use this antigen to produce new generations of vaccines. The main aim of this research is to investigate the ability to produce antibodies and immunogenicity of PA63 recombinant antigen loaded in PLGA nanoparticles in mice as a potential vaccine candidate. Methods: In this experimental study, the vector containing the PA63 gene was introduced into DE3 BL21 E. coli bacteria, and their transformation and protein expression levels were evaluated by PAGE-SDS. After purifying the recombinant proteins with column chromatography, the recombinant proteins were loaded in PLGA polymer and injected into mice three times in a row to study immunogenicity. Results: The size and zeta potential of nanoparticles containing nanoparticles containing PA63 protein were measured as 261.9 nm and -34.4 mV. Electron photographs taken of nanoparticles show the spherical shape of nanoparticles and the correct size and zeta potential of nanoparticles. The mean antibody titer produced against PA63 recombinant protein was increased in the loaded form compared to the free one. Conclusion: In this research, due to the advantages of nanoparticle systems in reducing possible protein risks and also the possibility of increasing its immunogenicity as new delivery systems of protein vaccines, nanoparticles based on natural and synthetic polymers containing PA63 protein were used. PLGA nanoparticles with different characteristics in terms of different physicochemical properties, release patterns, synthesis methods and loading rates were studied in order to determine the best form of polymer for protein loading.